| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies, Inc. | SVP, Genl Counsel, Acting CFO | Performance Based Stock Option (Right to Buy) | 75,257 | 14 Sep 2022 | Direct | ||
| Adverum Biotechnologies, Inc. | SVP, Genl Counsel, Acting CFO | Stock Option (Right to Buy) | 42,813 | 14 Sep 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ADVM | Adverum Biotechnologies, Inc. | 14 Sep 2022 | 2 | $0 | 4 | SVP, Genl Counsel, Acting CFO | 16 Sep 2022, 19:00 |
| ADVM | Adverum Biotechnologies, Inc. | 08 Jun 2022 | 1 | $0 | 4 | SVP, Genl Counsel, Acting CFO | 10 Jun 2022, 16:39 |
| ADVM | Adverum Biotechnologies, Inc. | 03 Jun 2022 | 0 | $0 | 3 | SVP, Genl Counsel, Acting CFO | 10 Jun 2022, 16:37 |